# Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

> **NCT07722741** · PHASE2 · RECRUITING · sponsor: **Geneos Therapeutics** · enrollment: 90 (estimated)

## Conditions studied

- HCC

## Interventions

- **BIOLOGICAL:** GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation
- **DEVICE:** Electroporation Device
- **BIOLOGICAL:** INO-9012

## Key facts

- **NCT ID:** NCT07722741
- **Lead sponsor:** Geneos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-09
- **Final completion:** 2032-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722741, "Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*